MoonLake Immunotherapeutics
No enriched coverage for $MLTX in the last 7 days.
Reich Kristian (Chief Scientific Officer) sold 52,448 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at an average of $20.02 ($20.00–$20.02, $1.05M total) across 2 trades over 2026-07-21 to 2026-07-22 under a Rule 10b5-1 trading plan.
Reich Kristian (Chief Scientific Officer) sold 43,700 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at $20.09 ($0.88M total) on 2026-07-20 under a Rule 10b5-1 trading plan.
Santos da Silva Jorge (Chief Executive Officer) sold 102,225 shares of MoonLake Immunotherapeutics (MLTX) at an average of $20.02 ($20.01–$20.02, $2.05M total) across 2 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
Recent MLTX coverage spans insider activity, financial news and sector analysis.
In the last 30 days, MLTX insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($4.3M). The most active reporter was Reich Kristian, Chief Scientific Officer, with 5 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited direct signal for fundamentals.
Routine 10b5-1 insider sale provides limited incremental signal, but confirms ongoing insider liquidity activity.
This is a routine insider sale under a 10b5-1 plan, with limited direct signal on fundamentals.
Insider selling via 10b5-1 is typically pre-planned, but it can still be read as a mild negative signal by some traders given the stock’s prior drawdown.
This is a routine insider sale disclosure tied to a pre-arranged 10b5-1 plan, with limited direct signal value.
alphai scores every news story that mentions MLTX with an AI model for sentiment and relevance, and aggregates insider trades from MoonLake Immunotherapeutics's SEC EDGAR Form 4 filings. Figures refresh continuously.
Reich Kristian (Chief Scientific Officer) sold 52,448 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at an average of $20.02 ($20.00–$20.02, $1.05M total) across 2 trades over 2026-07-21 to 2026-07-22 under a Rule 10b5-1 trading plan.
3 min readReich Kristian (Chief Scientific Officer) sold 43,700 indirectly-held shares of MoonLake Immunotherapeutics (MLTX) at $20.09 ($0.88M total) on 2026-07-20 under a Rule 10b5-1 trading plan.
2 min readSantos da Silva Jorge (Chief Executive Officer) sold 102,225 shares of MoonLake Immunotherapeutics (MLTX) at an average of $20.02 ($20.01–$20.02, $2.05M total) across 2 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
2 min readMoonLake Immunotherapeutics says its CFO sold about 39,000 shares under a 10b5-1 plan, with preset timing to avoid trading on material nonpublic information. The article notes the stock fell sharply in late September after disappointing study results and highlights the company has no approved products and no revenue, making shares sensitive to development news.
2 min readSantos da Silva Jorge (Chief Executive Officer) sold 47,775 shares of MoonLake Immunotherapeutics (MLTX) at $20.03 ($0.96M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
1 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readMoonLake Immunotherapeutics (MLTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ea029576601ex1-1.htm UNDERWRITING AGREEMENT, DATED JUNE 23, 2026, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AND LEERINK PARTNERS LLC Exhibit 1.1 MOONLAKE IMMUNOTHERAPEUTICS (a Cayman Islands exempted company) 9,000,000 Ordinary Shares Pre-Funded Warrants to Purchase up
2 min readMoonLake Immunotherapeutics (NASDAQ: MLTX) priced an underwritten public offering of 9,000,000 Class A ordinary shares at $20.00 each, plus pre-funded warrants for up to 1,000,000 shares at $19.9999. Gross proceeds are expected at about $200 million. An option allows underwriters to buy 1,500,000 more shares. Net proceeds will fund sonelokimab development and general corporate purposes; closing is expected around June 25, 2026.
2 min readBodenstedt Matthias (Chief Financial Officer) sold 39,120 shares of MoonLake Immunotherapeutics (MLTX) at $22.04 ($0.86M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
1 min readMoonLake Immunotherapeutics reported Week 52 Phase 3 VELA results for sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa. According to the company, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100; 26.0% reached IHS4-100. No new safety signals were seen. Interim VELA-TEEN Week 24 data showed ~68% HiSCR75. The company plans a BLA submission by end-September 2026 and will host an Investor Day webcast June 22, 2026.
6 min read
